At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-28
DOI
10.1038/s41571-022-00633-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
- (2022) Felipe Batalini et al. CLINICAL CANCER RESEARCH
- Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors
- (2021) Yanyan Cai et al. CANCER RESEARCH
- Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)
- (2021) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
- (2021) Komal Jhaveri et al. CLINICAL CANCER RESEARCH
- Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1
- (2021) Eva Maria Ciruelos et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
- (2021) Hope S Rugo et al. LANCET ONCOLOGY
- 338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer
- (2021) E. Hamilton et al. ANNALS OF ONCOLOGY
- Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
- (2021) Giuseppe Curigliano et al. EUROPEAN JOURNAL OF CANCER
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Christopher Sweeney et al. LANCET
- Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
- (2021) Bianca J. Lee et al. Nature Chemical Biology
- PI3K inhibitors are finally coming of age
- (2021) Bart Vanhaesebroeck et al. NATURE REVIEWS DRUG DISCOVERY
- AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B
- (2021) Jia Xu et al. Cancer Discovery
- RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy
- (2021) Kyung W Song et al. Cancer Discovery
- Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation
- (2021) Xiao Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
- (2021) Claudio Vernieri et al. Cancer Discovery
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- (2020) Robert H Jones et al. LANCET ONCOLOGY
- PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
- (2020) Kwanha Yu et al. NATURE
- Cracking the context-specific PI3K signaling code
- (2020) Ralitsa R. Madsen et al. Science Signaling
- Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes
- (2020) Ramon Parsons Cold Spring Harbor Perspectives in Medicine
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
- (2020) Lillian M Smyth et al. CLINICAL CANCER RESEARCH
- Landscape and function of multiple mutations within individual oncogenes
- (2020) Yuki Saito et al. NATURE
- Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids
- (2020) Nikos Koundouros et al. CELL
- Ras assemblies and signaling at the membrane
- (2020) Ruth Nussinov et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Fasting-mimicking diet and hormone therapy induce breast cancer regression
- (2020) Irene Caffa et al. NATURE
- 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)
- (2020) N. Turner et al. ANNALS OF ONCOLOGY
- Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
- (2020) Susana Ros et al. CANCER CELL
- Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer
- (2020) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition
- (2020) Jennifer M. Spangle et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
- (2020) Javier Pascual et al. Cancer Discovery
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
- (2020) Kevin Kalinsky et al. JAMA Oncology
- Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
- (2020) S. Dent et al. ANNALS OF ONCOLOGY
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- Direct stimulation of NADP+ synthesis through Akt-mediated phosphorylation of NAD kinase
- (2019) Gerta Hoxhaj et al. SCIENCE
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
- (2019) Pauline T. Lukey et al. EUROPEAN RESPIRATORY JOURNAL
- BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
- (2019) N C Turner et al. ANNALS OF ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner
- (2019) Ralitsa R. Madsen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression
- (2019) Eneda Toska et al. Cell Reports
- FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer
- (2019) Joshua Z Drago et al. CLINICAL CANCER RESEARCH
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- 456PFirst-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours
- (2019) M Yunokawa et al. ANNALS OF ONCOLOGY
- A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
- (2019) Lara A. Dunn et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- (2019) Neil Vasan et al. SCIENCE
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
- (2019) Andreas Schneeweiss et al. Cancers
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
- (2018) Sarika Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
- (2018) Jordi Rodon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
- (2018) Filip Mundt et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- (2018) Yu-Ru Lee et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- (2018) Matthew H. Bailey et al. CELL
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- Targeted therapy in patients with PIK3CA-related overgrowth syndrome
- (2018) Quitterie Venot et al. NATURE
- Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
- (2018) Ralitsa R. Madsen et al. TRENDS IN MOLECULAR MEDICINE
- IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
- (2018) Jonatan Zorea et al. Cell Death & Disease
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- 15 years of PhosphoSitePlus®: integrating post-translationally modified sites, disease variants and isoforms
- (2018) Peter V Hornbeck et al. NUCLEIC ACIDS RESEARCH
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition
- (2017) Sweta Maheshwari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α
- (2017) Lauren M. Thorpe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
- (2017) Eneda Toska et al. SCIENCE
- Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to Insulin
- (2017) Althea N. Waldhart et al. Cell Reports
- Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
- (2017) A. Biondo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate
- (2017) Larissa S. Moniz et al. Scientific Reports
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
- (2016) Pau Castel et al. CANCER CELL
- Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton
- (2016) Hai Hu et al. CELL
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
- (2016) J. Baselga et al. CLINICAL CANCER RESEARCH
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Obesity and Cancer Mechanisms: Cancer Metabolism
- (2016) Benjamin D. Hopkins et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
- (2016) X. Le et al. Cancer Discovery
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
- (2015) T. Dogruluk et al. CANCER RESEARCH
- A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
- (2015) C. X. Ma et al. CLINICAL CANCER RESEARCH
- 342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors
- (2015) D. Juric et al. EUROPEAN JOURNAL OF CANCER
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- The CPTAC Data Portal: A Resource for Cancer Proteomics Research
- (2015) Nathan J. Edwards et al. JOURNAL OF PROTEOME RESEARCH
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium
- (2015) Lydia WT Cheung et al. eLife
- Structural basis of nSH2 regulation and lipid binding in PI3Kα
- (2015) Michelle S. Miller et al. Oncotarget
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
- (2014) Lydia W.T. Cheung et al. CANCER CELL
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Akt Phosphorylation and Regulation of Transketolase Is a Nodal Point for Amino Acid Control of Purine Synthesis
- (2014) Arindam Saha et al. MOLECULAR CELL
- SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
- (2014) Jessica A. Gasser et al. MOLECULAR CELL
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of diverse signalling pathways by oncogenic PIK3CA mutations
- (2014) Xinyan Wu et al. Nature Communications
- Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition
- (2014) E. Gonzalez-Billalabeitia et al. Cancer Discovery
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- Genetically engineered mouse models of PI3K signaling in breast cancer
- (2013) Sjoerd Klarenbeek et al. Molecular Oncology
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
- (2013) A. B. Hanker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Ketone bodies as signaling metabolites
- (2013) John C. Newman et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium
- (2013) M. J. Ellis et al. Cancer Discovery
- Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 (PIK3CA)
- (2012) J. E. Burke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma
- (2011) H. S. Venkatesh et al. NEURO-ONCOLOGY
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases
- (2011) W-C Hon et al. ONCOGENE
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Noninvasive Detection of Target Modulation following Phosphatidylinositol 3-Kinase Inhibition Using Hyperpolarized 13C Magnetic Resonance Spectroscopy
- (2010) C. S. Ward et al. CANCER RESEARCH
- AKT regulates BRCA1 stability in response to hormone signaling
- (2010) Andrew C. Nelson et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
- (2010) R. B. Chagpar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities
- (2009) C. V. Dang et al. CLINICAL CANCER RESEARCH
- Knockin of mutant PIK3CA activates multiple oncogenic pathways
- (2009) John P. Gustin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A frequent kinase domain mutation that changes the interaction between PI3K and the membrane
- (2009) D. Mandelker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Negative Regulation of AKT Activation by BRCA1
- (2008) T. Xiang et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More